Beijing Beilu Pharmaceutical Co., Ltd. (SHE:300016)

China flag China · Delayed Price · Currency is CNY
9.49
-0.14 (-1.45%)
Apr 30, 2026, 2:35 PM CST
52.33%
Market Cap 5.42B
Revenue (ttm) 1.21B
Net Income (ttm) 92.73M
Shares Out 562.87M
EPS (ttm) 0.18
PE Ratio 53.50
Forward PE n/a
Dividend 0.05 (0.55%)
Ex-Dividend Date n/a
Volume 15,122,669
Average Volume 26,666,709
Open 9.51
Previous Close 9.63
Day's Range 9.43 - 9.66
52-Week Range 6.15 - 11.98
Beta 0.49
RSI 45.79
Earnings Date Apr 22, 2026

About SHE:300016

Beijing Beilu Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products in China. The company provides contrast agents, such as gadopentetate meglumine injection, gadobutrol injection, and gadobenate meglumine injection for MRI contrast; and iohexol injection, iopamidol injection, and iodixanol injection for CT contrast, as well as glimepiride and repaglinide tablets and jiuwei zhenxin granules. It also offers gadolinium-based agents, including gadopentetate dimeglumine and gadobutrol, as wel... [Read more]

Sector Healthcare
Founded 1992
Employees 1,173
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300016
Full Company Profile

Financial Performance

In 2025, SHE:300016's revenue was 1.21 billion, an increase of 22.54% compared to the previous year's 983.55 million. Earnings were 92.73 million, an increase of 579.29%.

Financial Statements

News

There is no news available yet.